Mortgaging New Treatments Kicks the Can on High Drug Prices
The launch price for one-time gene therapy Zolgensma presents various implications.
At $2.1 million for a one-time administration, Zolgensma is the most expensive drug in the U.S.
Novartis has proposed long-term financing contracts for Zolgensma, a strategy many payers support. These long term financing options do not create more money, but do create avenues for passing costs back to insurance beneficiaries in future premiums. The FDA expects to approve 10-20 cell and gene therapies per year by 2025. Collectively, these may treat tens of millions of Americans, raising questions about sustainability.
Read full editorial here.